ACT ENALAPRIL 16 MG
ENALAPRIL SODIUM (ENALAPRIL MALEATE) : 16 MG · DIN 02291908 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is ACT ENALAPRIL?
ACT ENALAPRIL 16 MG contains ENALAPRIL SODIUM (ENALAPRIL MALEATE) : 16 MG. It is listed in the Health Canada Drug Product Database under DIN 02291908, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 18-Aug-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACT ENALAPRIL used for?
Essential or renovascular hypertension; symptomatic congestive heart failure; left ventricular dysfunction (EF <=35%).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02291908 |
|---|---|
| Brand name | ACT ENALAPRIL |
| Generic / active ingredient | ENALAPRIL SODIUM (ENALAPRIL MALEATE) : 16 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 16 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09AA02 ENALAPRIL |
| AHFS class | 24:32.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 18-Aug-2017 |
| Original market date | 2007-10-17 00:00:00 |
How is it administered?
Hypertension: 10-40 mg/day. Heart Failure: 5-20 mg/day. Start low (2.5-5 mg). Max 40 mg/day. Administer once or twice daily. Splitting tablets is not advised.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard section 11 header present but content truncated).
How is it supplied?
2.5 mg, 5 mg, 10 mg, and 20 mg tablets available in blisters of 30 and HDPE bottles of 100 and 500.
Contraindications
Hypersensitivity; history of ACEI-related angioedema; hereditary/idiopathic angioedema; combo with aliskiren in diabetes/renal impairment; combo with neprilysin inhibitors (e.g., sacubitril).
Warnings and precautions
Risk of life-threatening angioedema; excessive hypotension (especially with diuretics/salt depletion); neutropenia/agranulocytosis; dual blockade of RAS; persistent dry cough.
What can be used instead?
Other Canadian products sharing ATC code C09AA02 ENALAPRIL. 36 of 100 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT ENALAPRIL | 2 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02291878 |
| ACT ENALAPRIL | 4 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02291886 |
| ACT ENALAPRIL | 8 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02291894 |
| APO-ENALAPRIL | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02019892 |
| APO-ENALAPRIL | 2.5 MG | TABLET | APOTEX INC | MARKETED | DIN 02020025 |
| APO-ENALAPRIL | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02019906 |
| APO-ENALAPRIL | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02019884 |
| ENALAPRIL | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02400677 |
| ENALAPRIL | 16 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02442981 |
| ENALAPRIL | 2 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02442957 |
Who else supplies ENALAPRIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ENALAPRIL appears in 2538 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.